pipeline expansion

Tarsus Pharma stock surges 20% as insider sells shares for tax withholding. Strong XDEMVY sales growth and improving margins offset insider transaction.

Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.

Energy Transfer expects 9.2-11.7% EBITDA growth in 2026 from completed projects, oil prices, and AI data center demand, offering a 7.2% dividend yield with 3-5% annual increases.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.

Energy Transfer offers higher yield (7.01% vs 6.01%) and growth potential through pipeline expansion, positioning it as a stronger MLP investment than Enterprise Products Partners for 2026.

Energy Transfer generated record $8.2B in distributable cash flow, far exceeding its 7.2% dividend requirements. The midstream company projects 9-12% EBITDA growth in 2026.